Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • From Code to Clinic: How AI Is (and Isn’t) Rewriting the Life of a Drug

    In this episode of William Blair Thinking Presents, Matt Larew, partner and equity research analyst covering life science tools and diagnostics, explains where AI is accelerating early discovery, why wet‑lab validation still matters, and what real progress looks like as adoption moves from hype to practice.

    Listen to the podcast

  • Wise Group, plc: Initiation of Research Coverage

    William Blair initiated research coverage of Wise Group, plc (WSE $14.50), a technology company focused on improving the cross-border payments market. Wise commenced its listing on the Nasdaq at the start of trading on May 11 and maintains a secondary listing on the London Stock Exchange.

    Read more

  • Arxis, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Arxis, Inc. (ARXS $35.03), a designer and manufacturer of proprietary, mission-critical electronic and mechanical components serving the aerospace, defense, and industrial technology markets.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures